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ABSTRACT
BackgroundThe Kidney DiseaseQuality of Life 36-item short form survey (KDQOL-36) is a widely used,
patient-reported outcome measure for patients on dialysis. Efforts to aid interpretation are needed.
Methods We used a sample of 58,851 dialysis patients participating in the Medical Education Institute
(MEI) KDQOL Complete program, and 443,947 patients from the US Renal Data System (USRDS) to
develop the KDQOL-36 Summary Score (KSS) for the kidney-targeted KDQOL-36 scales (Burdens of
Kidney Disease [BKD], Symptoms and Problems of Kidney Disease [SPKD], and Effects of Kidney Disease
[EKD]). We also used the MEI and USRDS data to calculate normative values for the Short Form-12 Health
Survey’s Physical Component Summary (PCS) and Mental Component Summary (MCS), and the KDQOL-
36’s BKD, SPKD, and EKD scales for the United States dialysis population. We used conﬁrmatory factor
analysis (CFA) models for KDQOL-36 kidney-targeted items, evaluated model ﬁt with the comparative ﬁt
index (CFI; .0.95 indicates good ﬁt) and root-mean-squared error of approximation (RMSEA; ,0.06
indicates good ﬁt), and estimated norms by matching the joint distribution of patient characteristics in
the MEI sample to those of the USRDS sample.
Results A bifactor CFA model ﬁt the data well (RMSEA=0.046, CFI=0.990), supporting the KSS (a=0.91).
Mean dialysis normative scoreswere PCS=37.8 andMCS=50.9 (scoredon a T-scoremetric); and KSS=73.0,
BKD=52.8, SPKD=79.0, and EKD=74.1 (0–100 possible scores).
Conclusions The KSS is a reliable summary of the KDQOL-36. The United States KDQOL-36 normative
facilitate interpretation and incorporation of patient-related outcome measures into kidney disease care.
J Am Soc Nephrol 30: 654–663, 2019. doi: https://doi.org/10.1681/ASN.2018100994
Stakeholder panels of kidney patients, nephrolo-
gists, psychometricians, and industry representa-
tives have called for the continued incorporation
of rigorously developed patient-reported out-
comes (PROMs) into clinical trials andhealthpolicy
studies.1–5 Health-related quality of life (HRQOL)
is often measured by PROMs, and the Centers for
Medicare andMedicaid Services (CMS)mandates that
all patients with ESRD have HRQOL assessed annu-
ally.6–8 The Kidney Disease Quality of Life 36-item
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short form survey (KDQOL-36) is one of themost widely-used
measures of HRQOL for patients with ESRD.9 The KDQOL-36
includes both generic and ESRD-speciﬁcHRQOL scales, which
facilitates comparison with other clinical subgroups as well as
offering speciﬁcity and responsiveness to change for elements
of HRQOL important to patients with ESRD.10
The psychometric properties of the KDQOL-36 have been
evaluated in United States patients on dialysis, but there is a
need for guidance on its interpretation to facilitate its use in
clinical practice.11,12 Normative values of a PROM that are
referenced to a relevant population are useful to help guide
interpretation. As an example, the National Institutes of
Health Patient-Reported OutcomeMeasurement Information
System (PROMIS) generic HRQOL measures have been
normed to the United States general population on a T-score
metric, with a mean of 50 and SD of 10, representing the
United States general population average and SD.13 In previ-
ous research, a Kidney Disease Component Summary (KDCS)
score that averaged 11 ESRD-targeted scales from the longer
KDQOL short form instrument was used in the Dialysis Out-
comes and Practice Patterns Study.7,14,15 Shortening measure
length and minimizing measure burden on patients is also
important, as these characteristics have the ability to ease im-
plementation of PROMs into practice. A composite score from
the KDQOL-36 short form (Burdens of Kidney Disease,
Symptoms and Problems of Kidney Disease, and Effects of
Kidney Disease) has not been constructed.
To facilitate implementation and interpretation of the
KDQOL-36 in clinical practice, we examine whether there is
psychometric support for a composite score of items from this
measure’s three kidney-targeted scales and to estimate norma-
tive values in the United States dialysis population for the
Short Form (SF-12) version 1 Physical Component Summary
(PCS), SF-12 version 1 Mental Component Summary (MCS),
the KDQOL-36 kidney-targeted scales, and the newKDQOL-36
composite score.
METHODS
Data and Patient Sample Selection
The primary dataset used in this study was provided by the
nonproﬁt Medical Education Institute (MEI), which admin-
isters the KDQOL Complete scoring program used primarily
by small dialysis organization clinics throughout the United
States.10 KDQOL Complete helps dialysis centers complete
and score the KDQOL-36 instrument and uses responses to
the KDQOL-36 scales to help develop personalized plans of
care for patients on dialysis. Additional information on the
KDQOLComplete program andMEI has been published else-
where.11 Because all data provided by the MEI were deidenti-
ﬁed, an institutional review board exemption was granted by
the University of California, Los Angeles Human Subjects Pro-
tection Committee (approval no. 17–000313), including
waiver of informed consent.
We started with a set of 77,072 surveys and analyzed data
from 58,851 patients in the MEI dataset after excluding 4090
surveys that were completed a second time by patients (i.e.,
only the ﬁrst survey completed was used for patients who
completed the survey multiple times). We excluded the fol-
lowing from our analyses: 1275 assessments with a missing
assessment date (n=1273) or missing all survey data (n=2),
585 assessments from patients under the age of 18, 336 assess-
ments from patients who had not yet started dialysis or who
had received a previous transplant, 10,534 patients with miss-
ing information on race and ethnicity, and 1401 patients who
self-identiﬁed as Native Hawaiian/Paciﬁc Islander because as
this ethnic subgroup was not included in the US Renal Data
System (USRDS) dataset. As a secondary analysis dataset used
for test-retest reliability estimation, we retained the second
assessments of patients who completed the KDQOL-36 twice
within 1–21 days (n=103). We used aggregated data from
443,947 patients on dialysis from the USRDS to represent
the United States dialysis population.16 Because the data
were aggregated, we did not have access to individual-level
patients, and therefore did not perform individual case selec-
tion comparable with the case selection performed for the
MEI dataset.
Measures
The KDQOL-36 has ﬁve scales, including two generic HRQOL
scales from the SF-12 version 1 (12 items total) and three
kidney-speciﬁc scales (24 items total). The SF-12 PCS and
MCS are scored on a T-score metric (mean=50, SD=10, in
the United States general population), with higher scores in-
dicating better HRQOL.12 The kidney-targeted scales include
Burden of Kidney Disease (four items; e.g., “My kidney disease
interferes too much with my life”), Symptoms and Problems
of Kidney Disease (12 items; e.g., “Washed out or drained?”),
and Effects of Kidney Disease (eight items; e.g., “Your ability to
work around the house”).13 The Burden of Kidney Disease
items are prompted with the context, “How true or false is each
of the following statements?” and have ﬁve response options that
range from “deﬁnitely true” to “deﬁnitely false.” The Symptoms
Signiﬁcance Statement
Reliable, valid, and interpretable patient-reported outcome mea-
sures for kidney patients are needed for patient monitoring and use
as outcomes in clinical trials. The Kidney Disease Quality of Life 36-
item short form survey (KDQOL-36) is often used with patients on
dialysis,but improvementsareneededto facilitate interpretabilityof
its scores. The authors calculate normative values for theKDQOL-36
scales referenced to the United States dialysis population, which
allowcomparisonofgroupmeansand individual scoreswithnational
averages, such as by dialysis centers when fulﬁlling their required
annual assessment of patients’ quality of life. The authors also cre-
ated the KDQOL-36 Summary Score (KSS), a composite of items
from the KDQOL-36’s kidney-targeted scales, which may be useful
when kidney-targeted health-related quality of life needs to be
summarized in a single score.
J Am Soc Nephrol 30: 654–663, 2019 Normative Values for KDQOL 36 and a New Summary Score 655
www.jasn.org CLINICAL RESEARCH
and Problems with Kidney Disease items are given the context,
“During the past 4 weeks, to what extent were you bothered by
each of the following?” and have ﬁve response options ranging
from “not at all bothered” to “extremely bothered.” The Effects
of Kidney Disease scale’s items ask patients, “How much does
kidney disease bother you in each of the following areas?” and
have ﬁve response options ranging from “not at all bothered” to
“extremely bothered.” Each of the KDQOL-36 kidney-targeted
scales are scored by transforming all items linearly to a 0–100
possible range and averaging the items in the scale. On the
KDQOL-36, higher scores indicate better HRQOL.14 For each
KDQOL-36 scale, we also present results in the T-score metric,
with a mean of 50 and SD of 10, in the United States dialysis
population.
Relevant clinical and demographic characteristics were
collected on theCMSForm2728 in the dialysis facilities or by
the dialysis facilities themselves for the MEI sample. We
measured age, sex, race/ethnicity, dialysis type (hemodial-
ysis, peritoneal dialysis), and presence of diabetes. The same
variables were obtained for the USRDS national dialysis
population.
Examination of a KDQOL-36 Composite
We examined whether a composite could be created from the
items from the KDQOL-36 Burden of Kidney Disease, Symp-
toms and Problems of Kidney Disease, and Effects of Kidney
Disease scales using multiple approaches. First, exploratory
factor analysis (EFA) was conducted using maximum likeli-
hood estimation (Supplemental Appendix 1). To determine
the number of factors to retain, we examined two criteria:
(1) the Kaiser rule, which retains the number of factors equal
to the number of eigenvalues .1; and (2) parallel analysis,
which retains the number of factors wherein eigenvalues
from the data analyzed are larger than the eigenvalues from
an EFA on a random dataset with the same number of obser-
vations and variables. In the presence of evidence from these
analyses, which includes a ratio of the ﬁrst to second eigen-
value .4,17 an exploratory bifactor model was estimated
using the psych package in R. This analysis extracts
Schmid–Leiman transformed factor loadings to determine
how well each item loads on a general factor in addition to
speciﬁc factors.18 This analysis also generates vh, a measure
of general factor saturation, or the proportion of total vari-
ance accounted for by the general factor.19vh values of$0.70
indicate that a measure is essentially unidimensional.20 Fi-
nally, we examined the explained common variance (ECV)
from this analysis. The ECV is computed as the ratio of the
general factor’s eigenvalue to the sum of all eigenvalues from
the analysis and, like the vh, is a measure of general factor
saturation. Values of $0.60 indicate the presence of a strong
general factor.20
Next, we conducted conﬁrmatory factor analysis (CFA)
model using the lavaan package in R.21 We compared several
factorial structures, each with different CFA models. First, we
ﬁt a unidimensional model, where all items were set to load on
onlyone factor (SupplementalAppendix2 [SupplementalFigure2]).
Next, we ﬁt a three-correlated-factors CFAmodel, which represents
the factor structure previously published for the KDQOL-
36.11 The three-correlated-factors model sets four items to
load on one factor representing Burdens of Kidney Disease
(Table 1, items i13–i16), 12 items to load on a second factor
representing Symptoms and Problems of Kidney Disease
(items i17–i28), and a third factor representing Effects of
Kidney Disease (items i29–i36). Each of these factors is al-
lowed to correlate with one another (Supplemental Appendix
2 [Supplemental Figure 3]). Finally, we ﬁt a bifactor model.
Thismodel evaluateshowwell a general factor, in addition to speciﬁc
factors, account for the latent structure of a measure.22 For this
model, we included three speciﬁc factors matching those from the
three-correlated-factors model, each with the same items loading
on the Burdens of Kidney Disease, Symptoms and Problems of
Kidney Disease, and Effects of Kidney Disease factors as
described above, except the factors are left uncorrelated. In addi-
tion, each item loads directly onto a general factor (Supplemental
Appendix 2 [Supplemental Figure 4]).Goodﬁt of a bifactormodel
to the data provides support for a composite summary score.
Because the KDQOL-36 items have ordered categorical
responses, CFA models were estimated using the diagonally
weighted least squares estimator.Model ﬁt was evaluated using
the model’s chi-squared statistic, the comparative ﬁt index
(CFI), and the root mean squared error of approximation
(RMSEA). Nonsigniﬁcant chi-squared statistics, CFI values
.0.95, and RMSEA values ,0.06 indicate good model ﬁt.23
However, it is worth noting that the chi-squared statistic is
sensitive to sample size and may be statistically signiﬁcant
(P,0.05) even in the presence of good model ﬁt when the
sample size is large.
We examined construct validity of a kidney-speciﬁc com-
posite by examining Pearson correlations between the com-
posite and the SF-12 PCS andMCS. The following conventions
were used to interpret the magnitude of correlation coefﬁ-
cients, which correspond to standardized effect sizes: small,
0.10#r,0.243; medium, 0.243#r,0.371; and large,
r$0.371.24 Finally, we examined reliabilities of the
KDQOL-36 scales using two approaches. First, coefﬁcient a
was used to estimate the internal consistency reliability of each
KDQOL-36 kidney-speciﬁc scale, both overall and for race/
ethnicity x age subgroups. Themagnitude ofa coefﬁcients was
assessed using the following standard cut-off criteria: accept-
able, 0.70#a,0.80; good, 0.80#a,0.90; and excellent,
a$0.90.25 Because of the nature of the scoring of the SF-12
version 1 PCS and MCS, coefﬁcient a does not provided an
appropriate estimate of reliability. Hence, we used the sub-
sample of patients with second assessments between 1–21 days
after the ﬁrst assessment, all scales’ test-retest reliability was
estimated for the overall sample (n=103) using intraclass cor-
relation coefﬁcients. The magnitude of intraclass correlation
coefﬁcients for test-retest reliability was assessed with the fol-
lowing cut-off criteria: marginal, ,0.40; good, 0.40–0.75; and
excellent, .0.75.26
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Calculating Normative Scores
Normative scores were estimated using weights to match the
joint distribution of age, sex, race/ethnicity, dialysis type, and
etiology of ESRD in the study sample to the United States
general dialysis population sourced from the USRDS.15 We
divided both the MEI (n=58,851) and USRDS (n=443,947)
samples into cells derived from nested demographic groups,
starting with sex at the highest level (male versus female). We
divided the sample within both sex groups into racial/ethnic
subgroups (Hispanic, non-Hispanic white, black, Asian,
American Indian), then by type of dialysis (hemodialysis
versus peritoneal dialysis), and then by etiology of ESRD (di-
abetes versus no diabetes). Finally, we divided each of these
subdivisions by age range (18–29, 30–44, 45–59, 60–74, and
$75 years). This created a matrix of 200 cells.
We calculated cell weights by dividing each cell percentage in
the USRDS sample by the corresponding cell percent from the
MEI sample to create the MEI weighted sample. For example,
among the USRDS sample, the cell percentage of patients who
were female, non-Hispanic White, on hemodialysis, with diabe-
tes, in the 45–59 age range was 1.443%, and the corresponding
cell percentage in the MEI sample was 1.383%, resulting in a
weight of 1.04 for this cell. This weight was used in the calculation
of mean scores for each of the KDQOL-36 scales using the survey
means procedure in SAS v9.4.27 Normative values were calculated
for the overall sample, as well as by race/ethnic and age groups.
RESULTS
Study Samples
The characteristics of the MEI sample, MEI weighted sample,
and USRDS sample are shown in Table 2. Differences were
apparent between demographic and clinical characteristics
between theMEI sample and theUSRDS sample. For example,
there was a 6.1% difference in the proportion of Hispanic
patients between the MEI sample and the USRDS sample.
After weighting the MEI sample (MEI weighted sample), the
proportions of patients in each different subgroup categories
differed by no greater than 0.1%.
KDQOL-36 Summary Score
The EFA results supported a three factor solution with strong
potential for a bifactor structure. The vh was 0.78, which ex-
ceeds the cut-off to evidence essential unidimensionality and
indicates that 78% of the items’ variance is explained by the
general factor. The ECV was 0.68, also exceeding the cut-off to
indicate essential unidimensionality. Results of these analyses
are given in the Supplemental Materials.
The single-factor CFAmodel ﬁt the data poorly (chi square,
143,137.08; degrees of freedom [df ], 252; P,0.001;
RMSEA=0.105; CFI=0.945). By comparison, both the three-
correlated-factors model (chi square, 51,252.81; df=249;
P,0.001; RMSEA=0.063; CFI=0.980) and the bifactor model
Table 1. Bifactor CFA model factor loadings for the KDQOL-36
Item
General
Factor
Speciﬁc Factor:
Burden of
Kidney Disease
Speciﬁc Factor:
Symptoms/Problems
of Kidney Disease
Speciﬁc Factor:
Effects of
Kidney Disease
My kidney disease interferes too much with my life (i13) 0.63 0.62 — —
Too much time is spent dealing with kidney disease (i14) 0.60 0.68 — —
I feel frustrated dealing with my kidney disease (i15) 0.67 0.48 — —
I feel like a burden on my family (i16) 0.61 0.32 — —
Soreness in your muscles? (i17) 0.53 — 0.33 —
Chest pain? (i18) 0.46 — 0.39 —
Cramps? (i19) 0.40 — 0.32 —
Itchy skin? (i20) 0.37 — 0.67 —
Dry skin? (i21) 0.41 — 0.65 —
Shortness of breath? (i22) 0.47 — 0.38 —
Faintness or dizziness? (i23) 0.50 — 0.35 —
Lack of appetite? (i24) 0.46 — 0.31 —
Washed out or drained? (i25) 0.65 — 0.30 —
Numbness in hands or feet? (i26) 0.47 — 0.34 —
Nausea or upset stomach? (i27) 0.51 — 0.36 —
Problems with your access/catheter site? (i28) 0.41 — 0.17 —
Fluid restriction? (i29) 0.57 — — 0.50
Dietary restriction? (i30) 0.61 — — 0.67
Your ability to work around the house? (i31) 0.75 — — 20.01
Your ability to travel? (i32) 0.70 — — 0.07
Being dependent on doctors and other medical staff? (i33) 0.75 — — 0.04
Stress or worries caused by kidney disease? (i34) 0.84 — — 20.01
Your sex life? (i35) 0.58 — — 0.02
Your personal appearance? (i36) 0.73 — — 0.02
—, item was not set to load on this factor.
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(chi square, 24,960.99; df=228; P,0.001; RMSEA=0.046;
CFI=0.990) ﬁt the data very well, but the bifactor model ﬁt
better (Table 3). Higher loadings on the general factor in com-
parison to speciﬁc factors indicates that the general factor ex-
plains more variance for the item, providing support for the
general factor. Of the 24 KDQOL-36 kidney-speciﬁc items,
only one item loaded on the general factor of the bifactormodel
at a magnitude of ,0.40 (range: 0.37–0.84): i20, “itchy skin.”
Only four of the 24 items had a higher loading on any of the
speciﬁc factors than on the general factor. One of these was
from the Burden of Kidney Disease scale, i14 (“too much time
is spent dealing with kidney disease”). Two were from the
Symptoms and Problems of Kidney Disease scale, i20 (“itchy
skin”) and i21 (“dry skin”), and the last item with a higher
loading on a speciﬁc factor was on the Effects of Kidney Disease
scale, i30 (“dietary restriction”).
The correlations among three factors were noteworthy in the
three-correlated-factors model: Burden of Kidney Disease with
Symptoms and Problems of Kidney Disease, r=0.57; Burden of
KidneyDisease with Effects of KidneyDisease, r=0.74; and Symp-
toms and Problems of Kidney Disease with Effects of Kidney
Disease, r=0.74. These correlations suggest the presence of a gen-
eral factor that underlies these three scales.
Informed by these results, we developed the KDQOL-36
Summary Score (KSS) scale.We averaged together the 24 items
from the Burden of Kidney Disease, Symptoms and Problems
of Kidney Disease, and Effects of Kidney Disease scales. In
addition to its original scoring on a 0–100 possible range,
the KSS was also scored on a T-score metric with a mean of
50 and an SD of 10 in the dialysis population.
EachKDQOL-36kidney-speciﬁc scale had a “good” coefﬁcient
a ($0.80), and the KSS had an “excellent” coefﬁcient a ($0.90),
at 0.91 (Table 4). Of note, none of the scales’ reliabilities could be
increased by removing items. Coefﬁcient a scores within race/
ethnicity x age subgroups were all in the range of the overall
sample’s estimates (Supplemental Appendix 3 [Supplemental Table
4]). For the test-retest sample (n=103), all KDQOL-36 kidney-
targeted scales and theSF-12PCShadexcellent test-retest reliabilities
(.0.75), and the MCS had good test-retest reliability (0.40–0.75)
(Table 4). The KSS correlated at a large magnitude with the SF-12
PCS (r=0.51; P,0.001) and MCS (r=0.59; P,0.001).
Normative Scores Referenced to the United States
Dialysis Population
Normative scores for the SF-12 PCS, SF-12MCS, KSS, Burden
ofKidneyDisease, Symptoms andProblems ofKidneyDisease,
and Effects of Kidney Disease referenced to the United States
dialysis population using the MEI weighted sample are
presented in Tables 4 and 5 as mean scale scores with 95%
conﬁdence intervals. Table 4 presents the overall sample nor-
mative scores in both the original scoring and T-score metrics.
As SEMs were small (0.04–0.12), estimates of normative
scores were precise.
Table 5 presents normative scores within age and race/
ethnicity groups on the T-score metric. For the SF-12 PCS,
scores decreasedmonotonically with age group, regardless of
Table 2. Dialysis patient characteristics in the MEI sample, MEI weighted sample, and prevalent adult United States national
dialysis sample from the USRDS
Patient Characteristics MEI Raw Sample, n=58,851 MEI Weighted Sample, n=58,846 USRDS Sample, n=443,947
Age, yr, % (n)
18–29 2.4 (1389) 2.2 (1276) 2.1 (9610)
30–44 10.5 (6196) 10.5 (6174) 10.4 (46,586)
45–59 29.1 (17,120) 28.4 (16,711) 28.4 (126,154)
60–74 38.5 (22,650) 38.4 (22,584) 38.4 (170,355)
$75 19.5 (11,498) 20.6 (12,101) 20.6 (91,242)
Sex, % (n)
Women 43.3 (25,458) 43.4 (25,567) 43.4 (192,787)
Men 56.7 (33,393) 56.6 (33,393) 56.6 (251,160)
Race/ethnicity, % (n)
Hispanic 23.1 (13,594) 17.0 (9995) 17.0 (75,447)
Non-Hispanic white 37.3 (21,972) 40.8 (24,008) 40.8 (181,091)
Non-Hispanic black 32.0 (18,855) 35.8 (21,048) 35.8 (158,788)
Non-Hispanic Asian 5.8 (3414) 5.3 (3414) 5.3 (23,498)
Non-Hispanic American Indian 1.7 (1016) 1.2 (1016) 1.2 (5123)
Dialysis type, % (n)
Hemodialysis 88.2 (51,904) 90.3 (53,141) 90.3 (400,920)
Peritoneal dialysis 11.8 (6947) 9.7 (5705) 9.7 (43,027)
Diabetes, % yes (n) 53.5 (31,522) 46.3 (27,269) 46.4 (205,807)
Table 3. Fit of CFA models for kidney-speciﬁc scales of the
KDQOL-36
Model RMSEA CFI Chi Square; df; P Value
Unidimensional 0.105 0.945 143,137.08; 252; P,0.001
Three-correlated-factors
model
0.063 0.980 51,252.81; 249; P,0.001
Bifactor model 0.046 0.990 24,960.99; 228; P,0.001
RMSEA good ﬁt ,0.06; CFI good ﬁt .0.95.
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race/ethnicity, indicating worsening HRQOL with age. Overall,
and for non-Hispanic white and black patients, the SF-12 MCS
scores were larger (more positive) with increasing age. The PCS
and MCS scores for non-Hispanic black patients were higher
than other race/ethnic groups, as has been observed in other
research.12 No speciﬁc patterns in the PCS or MCS across age
groups emerged for other race/ethnic groups.
Black patients had the highest (best HRQOL) KSS scores,
followed by non-Hispanic white patients, Hispanic patients,
and ﬁnally, Asian patients. No clear pattern in KSS scores
emerged across age groups. Black patients tended to have
the highest and Asian patients the lowest Burden of Kidney
Disease, Symptoms and Problems of Kidney Disease, and Ef-
fects of Kidney Disease scale scores. Strong patterns did not
emerge across age groups for these scales.
DISCUSSION
Theuse and relevance of PROMs in dialysis qualitymonitoring
and clinical research has increased in the past decade,1,2,15,28,29
and the KDQOL-36 is among the most common PROMs used
with patients on dialysis. Despite its widespread use, efforts to
aid interpretation of the KDQOL-36 scores are needed. This
study advances the current knowledge of how to interpret
scales of the KDQOL-36 by providing reference values for
the national United States dialysis population, overall and
for subgroups. In addition, a new KDQOL-36 composite,
the KSS summary scale, demonstrated excellent reliability
and allows ease of implementation of this PROM into clinical
practice and research studies.
Normative values referenced to the national United States
dialysis population, as represented in the USRDS, were calcu-
lated in both the original scoring metric of each KDQOL-36
scale and using a T-scoremetric that set each scale to amean of
50 with an SD of 10. These normative values make possible a
comparison of groups and individual patients to a national
“average” patient. As the value of 50 is referenced to the United
States national dialysis population average on the T-scoremet-
ric, an individual’s or patient group’s scores can be referenced
easily in terms of SD. For example, a group of patients on
dialysis with a mean T-score of 40 would be 1 SD worse
than the national average. T-scores are also used by mature
HRQOL measurement systems, including the Medical
Outcomes Study SF-3630,31 and PROMIS.13,32
Use of normative values have several important applications
for dialysis clinics and patients. The National Quality Forum
and expert reviews have listed appropriate normative values as
critical for interpretation of PROMs used as quality perfor-
mance measures.33,34 A dialysis clinic’s medical director may
want to compare the average score for his or her clinic to the
national average. This type of group-level comparison may
help facilitate quality improvement initiatives. For example, a
dialysis center may set a quality goal to exceed the clinic-level
national average forHRQOL, and these normative values could
assist in that project. On the individual level, similar compar-
isons can be made. Values below the national average may
signal a particularly sick or disabled patient who could beneﬁt
from amodiﬁed dialysis dose or from a referral (e.g., in the case of
low scores). These normative scores could also be utilized to en-
hance the dialysis patient–provider conversation. Because the
CMS requires patient-speciﬁc care plans on the basis of HRQOL
scores,35 the KDQOL-36 normative scores could assist in explain-
ing to patients how they compare with the national average. Cur-
rently, without additional interpretation from programs like
KDQOL Complete, patients on dialysis and providers may not
have the appropriate context to interpret HRQOL scale scores,
including the KDQOL-36 scales, and comparison to national
norms can give the scores context for what is “normal.”
Because scores have been calculated by age and racial/ethnic
group, these comparisons can be better targeted to a patient’s
demographic characteristics. Case-mix–adjusted norms, like
race/ethnicity-adjusted scores, can help to give additional con-
text to normative scores by providing reference values for the
adjusted group. For example, clinicians may choose to com-
pare their Asian, 49-year-old patient’s score on the KDQOL-36
Table 4. KDQOL-36 scale weighted means
Scale Mean SEM 95% Conﬁdence Interval Cronbach Test-Retest Reliability ICC
Original Scoring
SF-12 PCSa 37.8 0.04 37.7 to 37.9 — 0.81
SF-12 MCSa 50.9 0.04 50.8 to 51.0 — 0.63
KSS 73.0 0.07 72.9 to 73.1 0.91 0.88
KDQOL-36 Burden of Kidney Disease 52.8 0.12 52.6 to 53.1 0.85 0.80
KDQOL-36 Symptoms/Problems of Kidney Disease 79.0 0.07 78.9 to 79.2 0.83 0.89
KDQOL-36 Effects of Kidney Disease 74.1 0.09 74.0 to 74.3 0.85 0.82
T-scores
KSS 50.2 0.04 50.1 to 50.2 — —
KDQOL-36 Burden of Kidney Disease 50.2 0.04 50.1 to 50.3 — —
KDQOL-36 Symptoms/Problems of Kidney Disease 50.1 0.04 50.0 to 50.2 — —
KDQOL-36 Effects of Kidney Disease 50.1 0.04 50.0 to 50.2 — —
ICC, intraclass correlation coefﬁcient;—, not estimated.
aScored on T-score metric with mean of 50 and SD of 10 in United States general population.
J Am Soc Nephrol 30: 654–663, 2019 Normative Values for KDQOL 36 and a New Summary Score 659
www.jasn.org CLINICAL RESEARCH
Table 5. KDQOL-36 scale normative scores in T-score metric for race/ethnicity and age groups
Scale
All Races Hispanic Asian Black White
Mean (95% CI) Mean (95% CI) Mean (95% CI) Mean (95% CI) Mean (95% CI)
SF-12 PCS
All ages 37.8 38.8 38.3 39.2 36.0
(37.7 to 37.9) (38.6 to 38.9) (37.9 to 38.6) (39.1 to 39.4) (35.9 to 36.1)
18–29 yr 43.0 45.0 45.2 42.5 41.7
(42.4 to 43.5) (44.2 to 45.8) (43.2 to 47.2) (41.6 to 43.5) (40.6 to 42.7)
30–44 yr 40.7 42.0 41.8 41.2 38.8
(40.4 to 40.9) (41.6 to 42.5) (40.7 to 42.9) (40.8 to 41.6) (38.2 to 39.4)
45–59 yr 38.3 38.6 39.0 39.7 36.2
(38.1 to 38.4) (38.3 to 38.9) (38.3 to 39.7) (39.4 to 40.0) (35.9 to 36.5)
60–74 yr 37.2 38.3 38.1 38.5 35.6
(37.1 to 37.3) (38.0 to 38.6) (37.5 to 38.6) (38.3 to 38.8) (35.4 to 35.8)
$75 yr 36.1 36.6 35.9 37.4 35.4
(35.9 to 36.3) (36.1 to 37.1) (35.2 to 36.6) (37.0 to 37.8) (35.1 to 35.6)
SF-12 MCS
All ages 50.9 49.2 49.7 51.4 51.3
(50.8 to 51.0) (49.0 to 49.4) (49.4 to 50.1) (51.2 to 51.5) (51.2 to 51.4)
18–29 yr 49.8 49.5 49.4 50.6 49.2
(49.3 to 50.4) (48.7 to 50.4) (46.7 to 52.1) (49.7 to 51.6) (48.1 to 50.4)
30–44 yr 49.9 49.5 50.4 50.2 49.5
(49.6 to 50.1) (49.0 to 50.0) (49.3 to 51.5) (49.8 to 50.6) (49.0 to 50.1)
45–59 yr 50.1 48.6 49.5 51.0 50.0
(49.9 to 50.3) (48.3 to 48.9) (48.8 to 50.1) (50.8 to 51.2) (49.7 to 50.3)
60–74 yr 51.2 49.2 50.0 51.7 51.6
(51.0 to 51.3) (48.9 to 49.5) (49.5 to 50.6) (51.5 to 52.0) (51.4 to 51.8)
$75 yr 52.1 50.0 49.4 52.6 52.6
(51.9 to 52.3) (49.5 to 50.5) (48.6 to 50.2) (52.3 to 53.0) (52.4 to 52.9)
KSS
All ages 50.2 49.2 47.8 51.2 50.0
(50.1 to 50.2) (49.0 to 49.3) (47.4 to 48.2) (51.0 to 51.3) (49.8 to 50.9)
18–29 yr 50.2 50.5 51.0 50.3 49.9
(49.7 to 50.8) (49.7 to 51.3) (48.7 to 53.4) (49.3 to 51.3) (48.8 to 50.9)
30–44 yr 49.2 49.2 48.9 49.6 48.8
(49.0 to 49.5) (48.8 to 49.7) (47.8 to 50.0) (49.2 to 50.0) (48.3 to 49.4)
45–59 yr 49.2 48.2 47.4 50.5 48.4
(49.1 to 49.4) (47.9 to 48.5) (46.7 to 48.0) (50.3 to 50.8) (48.1 to 48.7)
60–74 yr 50.4 49.4 48.0 51.7 50.0
(50.3 to 50.5) (49.1 to 49.7) (47.5 to 48.6) (51.5 to 51.9) (49.8 to 50.2)
$75 yr 51.5 50.2 47.2 53.2 51.5
(51.3 to 51.6) (49.7 to 50.7) (46.4 to 48.0) (52.8 to 53.5) (51.3 to 51.7)
KDQOL-36 Burden of Kidney Disease
All ages 50.2 48.9 47.3 51.6 49.8
(50.1 to 50.3) (48.8 to 49.1) (47.0 to 47.6) (51.5 to 51.8) (49.7 to 49.9)
18–29 yr 49.5 49.6 49.1 49.6 49.3
(48.9 to 50.0) (48.8 to 50.4) (46.9 to 51.3) (48.7 to 50.6) (48.2 to 50.3)
30–44 yr 49.4 49.0 48.2 50.0 49.0
(49.2 to 49.7) (48.6 to 49.5) (47.1 to 49.3) (49.6 to 50.4) (48.5 to 49.5)
45–59 yr 49.7 48.1 47.1 51.3 48.9
(49.6 to 49.9) (47.8 to 48.4) (46.5 to 47.8) (51.1 to 51.6) (48.7 to 49.2)
60–74 yr 50.5 49.1 47.3 52.1 50.1
(50.3 to 50.6) (48.8 to 49.4) (46.8 to 47.9) (51.8 to 52.3) (49.9 to 50.3)
$75 yr 50.7 50.1 46.9 53.0 50.3
(50.5 to 50.9) (49.6 to 50.6) (46.2 to 47.6) (52.6 to 53.3) (50.1 to 50.6)
KDQOL-36 Symptoms and Problems of Kidney Disease
All ages 50.1 49.7 48.8 50.5 50.1
(50.0 to 50.2) (49.5 to 49.9) (48.4 to 49.2) (50.4 to 50.6) (49.9 to 50.2)
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Burdens of Kidney Disease scale to the adjusted normative
T-score of 47.1 instead of the general dialysis population
mean of 50. Therefore, in some cases, case-mix–adjusted
normative scores may be most appropriate. However, use of
case-mix–adjusted scoresmay alsomask disparities in HRQOL
between subgroups by normalizing a lower or higher level of
HRQOL in comparison to a reference subgroup. When con-
sidered at the clinic level, some have argued that case-mix ad-
justment can set a lower performance bar for clinics serving
many at-risk patients or incentivize serving patients at lower
risk to improve scores.36,37 For this reason, users should remain
cautious when comparing clinic-level scores to national norms
when these scores are stratiﬁed by race/ethnicity.
In addition to the KDQOL-36 scales’ normative values, this
study found evidence for a new composite of the KDQOL-36’s
Burdens of Kidney Disease, Symptoms and Problems of
Kidney Disease, and Effects of Kidney Disease items: the
KSS. There are some instances where a single, combined score
may be preferred to three separate kidney-speciﬁc scales, es-
pecially in research applications. For instance, in clinical
trials, a composite outcome is often preferable to multiple
separate outcomes because of higher reliability, statistical
power, and reducing multiple comparisons.38,39 The contin-
ued use of the Burdens, Symptoms and Problems, or Effects of
Kidney Disease scales is still recommended when themeasure-
ment of more speciﬁc outcomes is desired.
Other investigators have scored the KDCS from the larger
KDQOL Short Form instrument by combining all of its
11 scales.7,14,15,40 Although the KDCS has been shown to be
predictive of clinical outcomes, its psychometric properties
are unknown. Because the KDCS combines information
from a heterogeneous set of scales (which include measures
of cognitive function, satisfaction with care, etc.), further re-
search should be conducted to determine if it offers similar
reliability to that of the KSS. Although a single-score summary
representing the diverse constructs represented in the KDQOL
short form subscales could be useful, it is questionable
whether a coherent, unidimensional construct could be rep-
resented by such heterogeneous content.
This study has limitations that should be considered when
interpreting its results. First, research was not the original
objective of the data used in this study, which were collected
as part of the KDQOL Complete program to monitor the
physical and mental health of patients on dialysis. Because
of the sample’s size, we were able to draw a subsample repre-
sentative of the national dialysis population. However, a study
designed for this purpose that drew a probability sample
would have been able to cover more speciﬁc demographic
and clinical categories in its representation of the national di-
alysis population. Second, because of the deidentiﬁed nature
of the MEI data, we could not make patient-level links to the
USRDS dataset to enable statistical comparisons between the
cohorts. Third, although the dataset we used was rich in terms
of sample size and patient diversity, few clinical or other var-
iables were available to examine the KSS’s validity. We plan to
study the KSS’s construct validity in future research. Finally, there
Table 5. Continued
Scale
All Races Hispanic Asian Black White
Mean (95% CI) Mean (95% CI) Mean (95% CI) Mean (95% CI) Mean (95% CI)
18–29 yr 51.0 51.6 52.8 50.5 50.8
(50.4 to 51.5) (50.7 to 52.5) (50.2 to 55.4) (49.4 to 51.6) (49.7 to 51.8)
30–44 yr 49.7 50.6 50.1 49.6 49.4
(49.5 to 50.0) (50.1 to 51.1) (48.9 to 51.2) (49.2 to 50.0) (48.9 to 49.9)
45–59 yr 49.4 49.2 48.6 50.0 48.8
(49.2 to 49.5) (48.9 to 49.5) (47.9 to 49.4) (49.8 to 50.3) (48.5 to 49.1)
60–74 yr 50.2 49.7 49.0 50.8 50.0
(50.0 to 50.3) (49.4 to 50.0) (48.4 to 49.6) (50.6 to 51.1) (49.8 to 50.2)
$75 yr 51.0 49.8 47.9 51.6 51.4
(50.8 to 51.2) (49.3 to 50.3) (47.1 to 48.7) (51.2 to 52.0) (51.2 to 51.6)
KDQOL-36 Effects of Kidney Disease
All ages 50.1 49.0 47.9 51.2 50.0
(50.0 to 50.2) (48.9 to 49.2) (47.6 to 48.3) (51.0 to 51.3) (49.8 to 50.1)
18–29 yr 49.8 49.7 49.9 50.3 49.3
(49.2 to 50.4) (48.8 to 50.5) (47.6 to 52.1) (49.3 to 51.3) (48.3 to 50.4)
30–44 yr 48.9 48.3 48.5 49.3 48.6
(48.6 to 49.1) (47.8 to 48.8) (47.4 to 49.6) (48.9 to 49.7) (48.1 to 49.2)
45–59 yr 49.0 47.8 47.2 50.3 48.2
(48.8 to 49.1) (47.5 to 48.1) (46.5 to 47.9) (50.0 to 50.5) (47.9 to 48.5)
60–74 yr 50.4 49.6 48.3 50.8 49.9
(50.3 to 50.5) (49.3 to 49.9) (47.7 to 48.3) (50.6 to 51.1) (49.7 to 50.1)
$75 yr 51.9 50.6 47.8 53.7 51.8
(51.7 to 52.1) (50.1 to 51.0) (47.0 to 48.6) (53.4 to 54.1) (51.6 to 52.0)
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are several steps that still need to be taken to optimize the inter-
pretation of the KDQOL-36 that could not be covered by this
study. Perhaps most important among these is the estimation of
minimally important differences, or the smallest difference in
scores deemed important to a patient in terms of a change in
his or her health, or that would lead to a change in treatment
decisions.41 Estimationofminimally important differences for the
KDQOL-36 scales, including the newKSS, will help guide clinical
decision-making as well as estimate effect sizes for group differ-
ences to support planning of future research studies.
In conclusion, this study has advanced the use of the
KDQOL-36 in two ways. We created a new kidney-speciﬁc
HRQOL composite from the KDQOL-36 Burdens of Kidney
Disease, Symptoms and Problems of Kidney Disease, and
Effects of Kidney Disease items. The KSS composite captures
kidney-speciﬁc HRQOL in a single score. In addition, we
calculated normative values referenced to the national United
States dialysis population that can be used to compare with
group and individual scores on the KDQOL-36 scales, giving
context against the national average. These developments may
serve to improve the interpretation and implementation of the
KDQOL-36 instrument for patients and providers.
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